Yixi Shengwu is Drug Discovery in China that focus on developer business. Founded in 2019. They cover business area such as developer, intestinal microbiology pharmaceutical, tumor therapy, organism, ecology, intestinal micro-environment interaction, innovative pharmaceutical, depression, diabetes, tumor reconstitution, innovative microbial drug, patient, tumor chemotherapy.
2019
( 5 years old in 2024 )
Developer
-
940-7, Building A, Phase 1, Zhongdan Ecological Life-Science Industry Park
3-1 Xinjinhu Avenue, Jiangbei New District
Nanjing, Jiangsu
China
Private
developerintestinal microbiology pharmaceuticaltumor therapyorganismecologyintestinal micro-environment interactioninnovative pharmaceuticaldepressiondiabetestumor reconstitutioninnovative microbial drugpatienttumor chemotherapy
* We use standard office opening hours in near Yixi Shengwu's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Yixi Shengwu is Drug Discovery business from China that founded in 2019 (5 years old in 2024), Yixi Shengwu business is focusing on Developer.
Yixi Shengwu headquarter office and corporate office address is located in 940-7, Building A, Phase 1, Zhongdan Ecological Life-Science Industry Park 3-1 Xinjinhu Avenue, Jiangbei New District Nanjing, Jiangsu China.
Yixi Shengwu was founded in China.
In 2024, Yixi Shengwu is currently focus on developer sector.
Above is snippet of Google Trends for "developer" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Yixi Shengwu, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
